Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45results about How to "High radiochemical yield" patented technology

Fluorine-18-marked myocardial perfusion developing agent and preparation method and application thereof

The invention provides a fluorine-18-marked pyridazinone analogue. The general structural formula of the analogue is shown as a formula (A), wherein G is selected from S, O or NH; R1 is alkyl with 1-6 carbon atoms; R2 is halogen or halogenation alkyl; L is phenyl, cyclohexyl or a hexa-heterocycle radical containing heteroatoms; m is 1, 2, 3, 4, 5 or 6; n is an integer of 1-15; and M is methylene or ethoxy. A compound marking method is simple, and has high radiation chemistry yield, high stability, a high myocardium initial uptake value, high target to non-target ratio and low using cost. The pyridazinone analogue is applied to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine as a novel fluorine-18-marked myocardial perfusion developing agent.
Owner:BEIJING NORMAL UNIVERSITY +1

18F labeled compound and pod protease targeted PET imaging probe

The invention discloses an 18F-labeled compound and a pod protease targeted PET imaging probe, which relates to the technical fields of radiopharmaceuticals and nuclear medicine. The invention provides a compound shown as a formula (I), asparagine site shearing and disulfide bond reduction are carried out in a tumor microenvironment with high expression of pod protease, and a radioactive dimer 18F-1-dimer is formed by virtue of a biocompatible CBT-Cys click condensation reaction, so that the tumor imaging effect is improved. The compound with a structure shown in the formula (I) is synthesizedby adopting a one-step ion exchange 18F labeling method, the method is simple to operate, and preparative HPLC for further purification is not needed. The invention further provides the pod proteasetargeted PET imaging probe which is a compound shown in (I). The PET imaging probe has the advantages of high stability, high sensitivity, strong specificity, good safety and the like.
Owner:JIANGSU INST OF NUCLEAR MEDICINE

18F-labeled ethinyloestradiol and preparation method and application thereof

The present invention relates to the field of medicinal chemistry, and in particular relates to 18F-labeled ethinyloestradiol and a preparation method and application thereof, a modifying group is introduced into ethinylestradiol, and the ethinylestradiol is labeled by 18F, and the 18F-labeled ethinyloestradiol has good bioactivity, excellent pharmacokinetic properties and good stability in vitro, can be better targeting to breast cancer ER + cells, and can be used as a PET tracer for early diagnosis or therapeutic effect evaluation of high metastatic breast cancer ER + cells. The invention also provides the preparation method of the 18F labeled ethinylestradiol, a labeling group is introduced into the ethinylestradiol as a raw material by Click reaction, and heated for being exchanged with 18F<-> under relatively mild conditions, a labeling step and purification time are simplified, the radiochemical yield of the 18F-labeled ethinyloestradiol is high, and commercial application and clinical promotion of radiolabeled compounds are facilitated.
Owner:JIANGSU INST OF NUCLEAR MEDICINE

One-Step Labeling of Antibodies to High Specific Activity with Actinium-225

Provided herein is a one-step method for chelating actinium-225 to a construct comprising a chelator linked to a bio-molecule, such as, an antibody or monoclonal antibody, via a bifunctional ligand in, for example, a 3-arm configuration. Also provided are methods for increasing the radiochemical yield of an actinium-225-chelant-biomolecule complex and for producing a high specific activity actinium-225 complex. The chelation is performed at a physiological temperature, about 37° C. Also provided are high specific activity actinium-225 complexes, that is, actinium-225 chelated to the chelator-biomolecule construct and pharmaceutical compositions thereof. Further provided are methods of treating a neoplastic disease or disorder with the actinium-225 complexes.
Owner:SCHEINBERG DAVID A +3

Metal(LOID) chalcogen nanoparticles as universal binders for medical isotopes

The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and / or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Iodine isotope labeled benzyl phenyl ether derivatives, preparation method, pharmaceutical composition and application thereof

The invention discloses a class of iodine radioisotope labeled benzyl phenyl ether derivatives, a preparation method, a pharmaceutical composition and application thereof, and specifically relates toa benzyl phenyl ether derivative represented by a general formula I, a pharmaceutical salt, a stereoisomer and a preparation method thereof, a composition containing one or more radioactive compounds,and application of the radioactive compounds as PD-L1 tracers in human or animal bodies in diagnosis and treatment of diseases related to PD-1 / PD-L1 signaling pathways, such as cancer, infectious diseases and autoimmune diseases.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI

Preparation method and application of anilinoquinazoline compound

The invention provides an anilinoquinazoline compound, namely a quinazolinyl-4-anilino-2-(N,N,N-trialkyl) quaternary ammonium salt derivative, which is synthesized into a 2-[fluorine-18]fluoro substituted derivative through the radiochemistry and used as a fluorine-18 labeled precursor, and can be applied to the preparation of a tumor positron imaging agent; the tumor positron imaging agent adopts an epidermal growth factor as a target spot and can perform imaging of a specific tumor. According to the invention, the preparation method for the derivative has the following advantages: the synthesis steps are simple, and the target compound can be obtained at only one step that the quaternary ammonium salt precursor is labeled by the fluorine-18; the time for radiochemical synthesis is short, and only 20-25 min is required; the separation is simple and convenient without adopting HPLC, the product of which the radiochemical purity is more than 98 percent can be obtained with one Sep-Pak C-18 column, and meanwhile the quaternary ammonium salt precursor is removed; the radiochemical yield is high, the non-correction yield can reach 40-60 percent, and the drug specific radioactivity is high. The structural formula is shown in the specification.
Owner:ZHEJIANG UNIV

4-haloethenylphenyl tropane:serotonin transporter imaging agents

A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes and 4-haloethenylphenyl tropane families are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.
Owner:EMORY UNIVERSITY

Radioactive iodine marked Larotrectinib compound, and preparation method and application thereof

The invention relates to a radioactive iodine marked Larotrectinib compound, and a preparation method and application thereof. The provided compounds comprise the radioactive iodine marked Larotrectinib compound with the following structural formula and analogues of the compound, wherein R1 and R2 are selected from a group consisting of H, F, Cl, Br, 123I, 124I, 125I, 130I and 131I, and at least one of R1 and R2 is a radioactive iodine element. The invention provides the preparation method of the radioactive iodo-pyrazolo[1,5-a]pyrimidine compound and a preparation method thereof. A long half-life period and different ray energy of the radioactive iodo-pyrazolo[1,5-a]pyrimidine compound can be used for positron emission tomography (PET) development, and can also be applied to clinical diagnosis research of single-photon emission computed tomography (SPECT). Meanwhile, the high-energy radioactive iodo-pyrazolo[1,5-a]pyrimidine can be used as a TrK receptor ligand to inhibit activity ofTRK kinase to kill tumor cells, high-energy iodine-131-ray energy carried by the high-energy radioactive iodo-pyrazolo[1,5-a]pyrimidine can synergistically shoot tumor cells, and an accurate radiotherapy effect is achieved.
Owner:SHANGHAI UNIV OF MEDICINE & HEALTH SCI

Radiotracer introduced [18F]fluoromethyl group targeting neuroinflammation for PET imaging and Synthesis of Radiotracer and its biological evaluation Method for Radiotracer

Disclosed are an [18F]fluoromethyl group-introduced radiotracer for brain neuroinflammation-targeting positron emission tomography (PET), the synthesis thereof, and a method for evaluating biological results using the same. In the method for the synthesis of an [18F]fluoromethyl group-introduced radiotracer for brain neuroinflammation-targeting positron emission tomography, a compound obtained by introducing triazolium triflate into normethyl-PBR28 is used as a precursor and a fluoromethyl group is labeled with fluorine-18 in a single step. The [18F]fluoromethyl group-introduced radiotracer for brain neuroinflammation-targeting positron emission tomography is synthesized by using a compound, obtained by introducing triazolium triflate into normethyl-PBR28, as a precursor and performing substitution with fluorine-18 in a single step.
Owner:BIO IMAGING KOREA

Fluorinated phosphine oxide compound and application thereof in positron emission imaging

The invention relates to a fluorinated phosphine oxide compound used in the preparation of a positron emission imaging agent and a preparation method thereof, and has a structure shown in a formula I.For the first time, fluorinated phosphine oxide is used as an 18F-labeled auxiliary group, a positron nuclides probe is constructed by a 18F-19F isotope exchange strategy, a labeling method is mild in conditions, reactions can be directly conducted in an 18F-aqueous solution without blow-drying 18F-, and the compound has high radiochemical yield, easy purification, no need for high performance liquid chromatography separation and purification and broad application prospects in the field of positron drugs of preparing biomolecules such as heat sensitive and solvent sensitive peptides or proteins and the like.
Owner:XIAMEN UNIV

<18>F-labeled polypeptide compound, and preparation method and application thereof

The invention discloses a <18>F-labeled polypeptide compound with a structure represented by a formula 1. R1 is as shown in the formulas. R2 is C1-C10 straight-chain alkyl, C1-C10 branched-chain alkyl, C5-C7 cycloalkyl, polyethylene glycol, C6-C10 aryl, C6-C10 aryl-C1-C4 alkyl or C1-C4 alkyl-C6-C10 aryl-C1-C4 alkyl. The invention also provides a preparation method of the <18>F-labeled polypeptide compound. The method comprises the following steps: in a solvent, under Cu(I) catalysis, a compound D and a compound B are subjected to nitrine and terminal alkynyl 1,3-dipolar cycloaddition reaction. The invention also provides an application of the <18>F-labeled polypeptide compound. The <18>F-labeled polypeptide compound has the advantages of high imaging resolution and good stability. According to the preparation method of the <18>F-labeled polypeptide compound, the radiochemical yield is substantially improved compared to that of prior arts.
Owner:SHANGHAI INST OF APPLIED PHYSICS - CHINESE ACAD OF SCI

18F click labelling transferrin receptor targeting polypeptide T7 as well as preparation method and application thereof

The invention discloses 18F click labelling transferrin receptor targeting polypeptide T7 as well as a preparation method and application thereof. According to the preparation method, synthesis steps of click chemistry are improved, addition amount of a prosthetic group TsOTEGay is reduced, the addition amount of polypeptide T7 is appropriately increased, feeding ratio of the prosthetic group to the polypeptide T7 is adjusted to be 1:(1-2); after 18F-TEGay is synthesized through reaction, a polypeptide precursor is directly added for carrying out click reaction without carrying out HPLC purification, a 'one-pot two-step' process is adopted for synthesizing 18F-TEG-T7, and finally HPLC purification is carried out; and one purification process is reduced, the whole synthesis and purification time is greatly reduced and can be controlled to be within 120 minutes, radiochemical yield is about 28.26 minus and plus 7.43% (n=3). The optimized 'two-step one-pot' click reaction can be applied to research of 18F labelling polypeptide, and a novel tumor targeted probe can be prepared.
Owner:GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND

Radiolabeling of polypeptides

PendingUS20210017099A1Low chelator:antibody ratio (CAR)Stable radioimmunoconjugatesIsotope introduction to peptides/proteinsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesRadiolabelled antibody
Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.
Owner:JANSSEN BIOTECH INC

Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes

The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and / or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Fluorine-18-marked myocardial perfusion developing agent and preparation method and application thereof

The invention provides a fluorine-18-marked pyridazinone analogue. The general structural formula of the analogue is shown as a formula (A), wherein G is selected from S, O or NH; R1 is alkyl with 1-6 carbon atoms; R2 is halogen or halogenation alkyl; L is phenyl, cyclohexyl or a hexa-heterocycle radical containing heteroatoms; m is 1, 2, 3, 4, 5 or 6; n is an integer of 1-15; and M is methylene or ethoxy. A compound marking method is simple, and has high radiation chemistry yield, high stability, a high myocardium initial uptake value, high target to non-target ratio and low using cost. The pyridazinone analogue is applied to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine as a novel fluorine-18-marked myocardial perfusion developing agent.
Owner:BEIJING NORMAL UNIVERSITY +1

An estrogen receptor targeting radiotracer, preparation method and application

ActiveCN111407900BHigh ER affinityGood chemical stability and metabolic stability in vivoRadioactive preparation carriersSteroidsRadioactive tracerDimer
The invention discloses an estrogen receptor targeting radiotracer, a preparation method and an application. The tracer is a dimer structure of ethinyl estradiol, and its molecule includes two identical 17α-ethinyl estradiol groups. Through a short polyethylene glycol chain, the "click" chemical reaction is used to label the radioactive signal group in one step. group prepared. The tracer has high uptake in estrogen receptor-positive uterus, ovary, breast cancer cells and tumors, and can distinguish estrogen-positive receptors from estrogen-negative receptors in vivo and in vitro, with strong specificity , meeting the conditions for being used as an estrogen receptor imaging agent for breast cancer. The structural formula of the tracer is:
Owner:XIAMEN UNIV

A sort of 18 F-labeled benzimidazole compound and its preparation method and application

The invention provides an 18F marked benzimidazole compound as well as a preparation method and application thereof. The benzimidazole compound is 2-[(1-methyl-1-methylamino)carbamide-1-cyclohexyl-carbonyl-3-hydroxyl-pyrrole]-3-(4-fluoro-phenyl)-imidazole. With high radiochemical yield and non-correction yield reaching up to 80% and high specific activity, the 18F marked benzimidazole compound issuitable for PET tumor imaging, and has a relatively high tumor uptake value and a value for the examination and diagnosis as well as radiotherapy of tumor. In the invention, the raw materials for preparing an 18F marked precursor compound are cheap and easily available, the preparation process is simple and easy to control, and the reaction conditions are mild; meanwhile, the synthesis efficiencyis effectively improved, and the 18F marked benzimidazole compound has a good prospect in industrialized application and a high value in practical application.
Owner:SHANDONG UNIV QILU HOSPITAL

<18>F-labeled PI3K/Akt signal path inhibitor S14161, and preparation method and application thereof

ActiveCN106543131AC-F bond strengthThere will be no off-label phenomenonRadioactive preparation carriersIsotope introduction to organic compoundsChemical synthesisAkt signalling
The invention discloses a <18>F-labeled-8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14161) and a preparation method thereof. The preparation method has the following advantages: preparation raw materials are cheap and are easy to obtain, the synthesis process is simple, reaction conditions are mild, and the radiochemical synthesis time is short; the above product is simple and convenient to purify and separate, the radiochemical purity of the product exceeds 98%, the radiochemical yield of the product is high, the uncorrected yield reaches up to 92%, and the radioactivity of the product is high; and the product is useful in the inspection and diagnosis of tumors and the radiation therapy of the tumors. The structural formula of the <18>F-labeled-8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene is shown in the description.
Owner:SHANDONG UNIV QILU HOSPITAL

Radioactive i-labeled larotrectinib compound and preparation method and application thereof

The invention relates to a radioactive I-labeled Larotrectinib compound and a preparation method and application thereof, including a radioactive I-labeled Larotrectinib compound having the following structural formula and its analogs:where R1 and R2 are respectively H, F, Cl, Br, 123I, 124I, 125I, 130I or 131I, and at least one of R1 and R2 is a radioactive iodine element. The invention provides a preparation method of a radioiodinated pyrazolo[1,5-a]pyrimidine compound base. Radioiodinated pyrazolo[1,5-a]pyrimidine compounds with long half-life and different ray energy can be used for PET tomography and clinical diagnostic research of SPECT. Moreover, the high-energy radioiodinated pyrazolo[1,5-a]pyrimidine can act as a TrK receptor ligand to inhibit the activity of TRK and kill tumor cells; and due to high-energy I-131 ray energy carried, the radioiodinated pyrazolo[1,5-a]pyrimidine can coordinate to shoot tumor cells and thus achieve an accurate radiotherapy effect.
Owner:SHANGHAI UNIV OF MEDICINE & HEALTH SCI

Method for producing precursors for l-3,4-dihydroxy-6-[18f]fluorophenylalanine and 2-[18f]fluoro-l-tyrosine and the a-methylated derivatives thereof, precursor, and method for producing l-3,4dihydroxy-6-[18f]fluorophenylalanine and 2-[18f]fluoro-l-tyrosine and the a-methylated derivatives from the precursor

Disclosed is a method for producing precursors for L-3,4-dihydroxy-6-[18F]fluorophenylalanine and 2-[18F]fluoro-L-tyrosine and the α-methylated derivatives thereof, the precursor, and to a method for producing L-3,4-dihydroxy-6[18F]fluorophenylalanine and 2-[18F]fluoro-L-tyrosine and the α-methylated derivatives thereof from the precursor. A compound of formula (3) is provided which enables automated synthesis of L-3,4-dihydroxy-6-[18F]fluorophenylalanine and 2-[18F]fluoro-L-tyrosine. The enantiomeric purity of the product is ≧98%.
Owner:WAGNER FRANZISKA +2

Radioligands for imaging lpa1 receptor

The present invention relates to radiolabeled LPA1 receptor antagonists of Formula (I) or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein, which are useful for the quantitative imaging of LPA1 receptors in mammals.
Owner:BRISTOL MYERS SQUIBB CO

Quinazoline compound and preparation method and application thereof

The invention discloses a quinazoline compound and a preparation method and application thereof. The quinazoline compound as a medical developer has stable structure and high developing resolution. The preparation method is simple to perform, has short reaction time and high radioactive chemical yield and is easy to apply to industrial large-scale production.
Owner:SHANGHAI INST OF APPLIED PHYSICS - CHINESE ACAD OF SCI

An activatable tumor apoptosis pet imaging agent and its preparation method and application

The invention belongs to the field of radioactive medicine labeling, and in particular to an activatable tumor apoptosis PET (positron emission computed tomography) developer, as well as a preparationmethod and application thereof. The activatable tumor apoptosis PET developer has a structure as shown in a formula (I), the labeling process only needs 30 minutes, the labeling time is short, the radiochemical yield of the labeling product can reach 54 percent, the specific activity is 1.2 Ci / umol, the radiochemical purity is more than 98 percent, the labeling efficiency is high, the stability is high and the preparation steps are simple. The labeling product has high in-vitro stability, has high targeting property on apoptotic cells, can serves as a PET developer to detect tumor apoptosis,and also can be applied to early diagnosis of related diseases caused by abnormal cell apoptosis, detection progress, early curative effect evaluation after treatment or development of new treatment schemes and personalized diagnosis and treatment schemes.
Owner:JIANGSU INST OF NUCLEAR MEDICINE

A sort of 18 f-labeled compounds and pod protease-targeted pet imaging probes

The invention discloses a method in the technical field of radiopharmaceuticals and nuclear medicine 18 F-labeled compound and leguminase-targeted PET imaging probe. The present invention provides a compound represented by formula (I), which undergoes cleavage of asparagine sites and reduction of disulfide bonds in the tumor microenvironment with high expression of pod protease, and utilizes biocompatible CBT-Cys click condensation reaction, form radioactive dimers 18 F‑1‑dimer, which increases tumor imaging. The present invention adopts "one-step ion exchange" 18 The compound with the structure shown in formula (I) is synthesized by the F labeling method, and the method is simple to operate and does not require further purification by preparative HPLC. The present invention also provides a PET imaging probe targeting pod protease, which is the compound shown in (I). The PET imaging probe has the advantages of stability, high sensitivity, strong specificity, good safety and the like.
Owner:JIANGSU INST OF NUCLEAR MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products